These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27712055)

  • 1. Discovery and Characterization of Allosteric WNK Kinase Inhibitors.
    Yamada K; Zhang JH; Xie X; Reinhardt J; Xie AQ; LaSala D; Kohls D; Yowe D; Burdick D; Yoshisue H; Wakai H; Schmidt I; Gunawan J; Yasoshima K; Yue QK; Kato M; Mogi M; Idamakanti N; Kreder N; Drueckes P; Pandey P; Kawanami T; Huang W; Yagi YI; Deng Z; Park HM
    ACS Chem Biol; 2016 Dec; 11(12):3338-3346. PubMed ID: 27712055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.
    Yamada K; Levell J; Yoon T; Kohls D; Yowe D; Rigel DF; Imase H; Yuan J; Yasoshima K; DiPetrillo K; Monovich L; Xu L; Zhu M; Kato M; Jain M; Idamakanti N; Taslimi P; Kawanami T; Argikar UA; Kunjathoor V; Xie X; Yagi YI; Iwaki Y; Robinson Z; Park HM
    J Med Chem; 2017 Aug; 60(16):7099-7107. PubMed ID: 28771350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
    Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM
    Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration.
    Zhu W; Begum G; Pointer K; Clark PA; Yang SS; Lin SH; Kahle KT; Kuo JS; Sun D
    Mol Cancer; 2014 Feb; 13():31. PubMed ID: 24555568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of WNK signaling inhibitors as a new class of antihypertensive drugs.
    Ishigami-Yuasa M; Watanabe Y; Mori T; Masuno H; Fujii S; Kikuchi E; Uchida S; Kagechika H
    Bioorg Med Chem; 2017 Jul; 25(14):3845-3852. PubMed ID: 28566208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic mechanism and inhibitor characterization of WNK1 kinase.
    Yagi YI; Abe K; Ikebukuro K; Sode K
    Biochemistry; 2009 Nov; 48(43):10255-66. PubMed ID: 19739668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.
    Han W; Ding Y; Xu Y; Pfister K; Zhu S; Warne B; Doyle M; Aikawa M; Amiri P; Appleton B; Stuart DD; Fanidi A; Shafer CM
    J Med Chem; 2016 Apr; 59(7):3034-45. PubMed ID: 27002243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors.
    Xiao D; Palani A; Huang X; Sofolarides M; Zhou W; Chen X; Aslanian R; Guo Z; Fossetta J; Tian F; Trivedi P; Spacciapoli P; Whitehurst CE; Lundell D
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3262-6. PubMed ID: 23602398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisubstrate inhibitor approach for targeting mitotic kinase Haspin.
    Kestav K; Lavogina D; Raidaru G; Chaikuad A; Knapp S; Uri A
    Bioconjug Chem; 2015 Feb; 26(2):225-34. PubMed ID: 25595038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.
    Panicker RC; Chattopadhaya S; Coyne AG; Srinivasan R
    Adv Exp Med Biol; 2019; 1163():253-278. PubMed ID: 31707707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
    Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
    Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay.
    Wang W; Mevellec L; Liu A; Struble G; Miller R; Allen SJ; Federowicz K; Wroblowski B; Vialard J; Ahn K; Krosky D
    Biochemistry; 2021 Oct; 60(41):3114-3124. PubMed ID: 34608799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric small-molecule kinase inhibitors.
    Wu P; Clausen MH; Nielsen TE
    Pharmacol Ther; 2015 Dec; 156():59-68. PubMed ID: 26478442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and characterization of novel allosteric FAK inhibitors.
    Iwatani M; Iwata H; Okabe A; Skene RJ; Tomita N; Hayashi Y; Aramaki Y; Hosfield DJ; Hori A; Baba A; Miki H
    Eur J Med Chem; 2013 Mar; 61():49-60. PubMed ID: 22819505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of allosteric inhibitors of p21-activated kinase.
    Viaud J; Peterson JR
    Methods Mol Biol; 2012; 928():67-79. PubMed ID: 22956134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1.
    Patel O; Dai W; Mentzel M; Griffin MD; Serindoux J; Gay Y; Fischer S; Sterle S; Kropp A; Burns CJ; Ernst M; Buchert M; Lucet IS
    Structure; 2016 Sep; 24(9):1550-61. PubMed ID: 27545623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.